KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Current Investments: 2010-2024

Historic Cash & Current Investments for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $453.6 million.

  • Supernus Pharmaceuticals' Cash & Current Investments fell 30.27% to $281.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 32.08%. This contributed to the annual value of $453.6 million for FY2024, which is 77.97% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Cash & Current Investments stood at $453.6 million for FY2024, which was up 77.97% from $254.9 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Cash & Current Investments high stood at $461.3 million for FY2022, and its period low was $254.9 million during FY2023.
  • For the 3-year period, Supernus Pharmaceuticals' Cash & Current Investments averaged around $389.9 million, with its median value being $453.6 million (2024).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Cash & Current Investments plummeted by 44.75% in 2023, and later skyrocketed by 77.97% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash & Current Investments (Yearly) stood at $422.5 million in 2020, then dropped by 19.61% to $339.7 million in 2021, then surged by 35.81% to $461.3 million in 2022, then plummeted by 44.75% to $254.9 million in 2023, then skyrocketed by 77.97% to $453.6 million in 2024.